The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The importance of identifying patients with limited-stage DLBCL
Eliza Hawkes, MBBS Hons, FRACP, DMedSc, Olivia Newton-John Cancer Research Institute at Austin Health, Heidelberg, Australia, comments on the importance of correctly identifying patients with diffuse large B-cell lymphoma (DLBCL) who have limited-stage disease as this entity makes up approximately a quarter of all cases of DLBCL. Limited-stage DLBCL may require less treatment than advanced-stage disease, meaning some patients may be over-treated and experience excess toxicity and costs if clinicians do not appropriately stage and prognosticate them. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
